Journal of Alzheimer's & Dementia Open Access

Mechanisms Behind Synaptic Degeneration in Alzheimer's Disease and Potential Interventions

Rebecca Thomas^* Department of Neurology, Merrick University, Toronto, Canada
^*Correspondence: Rebecca Thomas, Department of Neurology, Merrick University, Toronto, Canada, Email:

, Manuscript No. IPAD-25-23378; Editor assigned: 28-Aug-2025, Pre QC No. IPAD-25-23378 (PQ); Reviewed: 11-Sep-2025, QC No. IPAD-25-23378; Revised: 18-Sep-2025, Manuscript No. IPAD-25-23378 (R); Published: 25-Sep-2025, DOI: 10.36648/ipad.25.8.66

Description

Synaptic degeneration is a central feature of Alzheimer’s disease, one of the most prevalent neurodegenerative disorders worldwide. This process involves the gradual loss of synapses, which are the vital communication points between neurons. The degeneration of synapses disrupts the normal flow of signals in the brain, leading to cognitive deficits, including memory loss and impaired learning. Understanding the mechanisms behind synaptic degeneration is essential for developing effective treatments and preventive strategies for Alzheimer's disease. In Alzheimer’s disease, synaptic degeneration is closely associated with the accumulation of amyloid-beta plaques and tau tangles, two hallmark features of the disease. Amyloid-beta is a protein fragment that, when improperly processed, aggregates to form plaques that disrupt the normal functioning of synapses. These plaques can interfere with neurotransmission, impairing the ability of neurons to communicate effectively. The buildup of amyloidbeta has been linked to the activation of microglia, the brain’s immune cells, which become overactive and contribute to neuroinflammation. This chronic inflammation further exacerbates synaptic damage, accelerating cognitive decline.

Tau, a protein that stabilizes microtubules in healthy neurons, also plays a Important role in synaptic degeneration in Alzheimer’s disease. In its abnormal form, tau forms tangles inside neurons, destabilizing the microtubules and disrupting the transport of essential molecules. As a result, the function of synapses is compromised and neurons begin to deteriorate. The spread of tau pathology throughout the brain follows a predictable pattern, beginning in the entorhinal cortex and hippocampus, regions critical for memory formation. This progressive spread of tau tangles is thought to contribute to the worsening of cognitive symptoms in Alzheimer’s patients.

Inflammation also plays a critical role in synaptic degeneration in Alzheimer’s disease. As amyloid plaques accumulate in the brain, they activate microglia, the resident immune cells in the central nervous system. In response to the plaques, microglia release inflammatory cytokines and other molecules that can damage synapses and neurons. While inflammation is a natural response to injury or infection, chronic inflammation in Alzheimer’s disease can become detrimental. In fact, neuroinflammation has been identified as one of the driving forces behind synaptic degeneration and controlling this inflammation may help slow disease progression.

There are also genetic factors that influence the extent of synaptic degeneration in Alzheimer’s disease. Mutations in certain genes, such as the Amyloid Precursor Protein (APP) gene and the presenilin genes, can lead to an increased production of amyloid-beta, thereby enhancing plaque formation. Additionally, variations in the Apolipoprotein E (APOE) gene have been linked to an increased risk of developing Alzheimer’s disease. APOE is involved in lipid metabolism and the clearance of amyloid-beta and certain genetic variants of APOE are less effective at removing amyloid plaques, contributing to the buildup of amyloid in the brain. Understanding these genetic factors provides valuable insights into the molecular mechanisms of synaptic degeneration and may lead to the development of targeted therapies.

In addition to cholinesterase inhibitors, other approaches are being explored, including immunotherapy to target amyloid plaques and tau tangles. Passive immunization, in which antibodies are used to clear amyloid-beta from the brain, has shown promise in early-stage clinical trials. Active immunization, which aims to stimulate the body’s immune system to produce its own antibodies against amyloid-beta, is another area of active research. Although these therapies have shown mixed results, they offer hope for slowing the progression of synaptic degeneration. Gene therapy is another potential avenue for intervention. By targeting specific genes involved in the production of amyloid-beta or tau, researchers hope to reduce the accumulation of these proteins and prevent synaptic damage. For example, gene silencing techniques, such as Ribonucleic Acid (RNA) interference, have been used to inhibit the production of amyloid-beta in animal models of Alzheimer’s disease. These approaches are still in the early stages of development but represent an exciting frontier in the fight against neurodegenerative diseases.

Conclusion

In conclusion, synaptic degeneration is a fundamental process in Alzheimer’s disease, driven by the accumulation of abnormal proteins, oxidative stress, mitochondrial dysfunction and inflammation. Understanding these mechanisms provides valuable insight into the causes of cognitive decline and offers potential therapeutic targets. While current treatments provide some symptomatic relief, ongoing research into immunotherapy, gene therapy and lifestyle interventions may eventually lead to more effective ways to prevent or reverse synaptic degeneration, improving outcomes for individuals affected by Alzheimer’s disease.